18.01.2011 • News

Lanxess Invests €40 Million in 2 Projects at Krefeld-Uerdingen Site

Laying the foundation stone (from left to right): Hubert Fink, head of the...
Laying the foundation stone (from left to right): Hubert Fink, head of the Lanxess business unit Basic Chemicals; Werner Breuers, member of the board of management of the Lanxess AG; construction manager Alexander Kerns; and Gregor Kathstede, mayor of Krefeld.

Lanxess has announced a €40 million investment in two projects at its Krefeld-Uerdingen, Germany site.The company is building a production plant for the formalin needed to make trimethylolpropane (TMP). The applications of this trivalent alcohol include numerous products used in the furniture, construction and automotive industries. In addition to the plant itself, new formalin and methanol tanks will also be built on a total area of 1,000 m2 and is due to start up at the end of 2011.

In addition, the company said it is responding to strong global demand for menthol by investing in the expansion of its existing menthol production facilities. Synthetic menthol is a key component of numerous aromas and pharmaceutical products. Lanxess - in collaboration with Symrise - is the world's leading manufacturer of synthetic menthol and thymol. Initial planning work on the expansion of the hydrogenation facility is already under way, and the project is due to be completed during the first half of 2012.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.